425: Semler Scientific Streamlines Operations Amid Strive Merger

Semler Scientific announces a 37% headcount reduction and cost-saving measures while implementing a retention program ahead of its proposed all-stock merger with Strive, Inc.

Summary

• Semler Scientific's board of directors approved a strategic realignment plan, including an approximate 37% headcount reduction and curtailment of other operating expenses, expected to be completed by the end of calendar 2025.
• The headcount reduction is anticipated to result in a quarterly operating expense reduction of approximately $0.7 million to $1.1 million in base salary, beginning in January 2026.
• Semler Scientific estimates it will incur approximately $1.2 million in severance costs, payable in December 2025 and January 2026.
• A time-based cash retention program for remaining non-executive employees is being implemented at an estimated cost of $1.6 million to ensure continuity during the proposed merger with Strive, Inc. and through any integration period.
• The proposed merger with Strive, Inc. is an all-stock transaction, initially disclosed on September 22, 2025, and amended on December 3, 2025.
• Strive, Inc. announced a letter agreement with Vivek Ramaswamy on December 3, 2025, regarding the potential conversion of Strive's Class B common stock into Class A common stock.
• Strive, Inc. entered into a Controlled Equity Offering Sales Agreement to offer and sell up to $500,000,000 of its Variable Rate Series A Perpetual Preferred Stock (SATA Stock).
• Strive, Inc. filed a Certificate of Amendment on December 9, 2025, to increase the authorized shares of its SATA Stock to 20,000,000.
• Strive, Inc. declared a cash dividend of $1.1333 per share on its SATA Stock, payable on December 15, 2025, to stockholders of record on December 1, 2025, with the dividend accrued from November 10, 2025.

Sentiment

Score: 4

Explanation: The filing presents a mixed bag. The significant headcount reduction and associated costs are negative, indicating operational challenges. However, the stated goal of improving operating leverage and the implementation of a retention program are positive steps to stabilize the company during a merger. The merger itself, while potentially strategic, introduces integration risks. Strive's capital raise and dividend activity show active financial management, but the overall sentiment for Semler is cautious due to the restructuring.

Positives

• Strategic realignment and headcount reduction are expected to improve operating leverage and reduce quarterly operating expenses by $0.7 million to $1.1 million in base salary starting January 2026.
• Implementation of a non-executive retention program aims to ensure business continuity and support functions during the proposed merger with Strive, Inc. and the subsequent integration period.

Negatives

• A significant headcount reduction of approximately 37% indicates a substantial restructuring and potential operational challenges.
• Semler Scientific expects to incur approximately $1.2 million in one-time severance costs.
• The non-executive retention program will cost an estimated $1.6 million.

Risks

• Volatility in Bitcoin and other risks related to Semler Scientific's Bitcoin treasury strategy and its healthcare business.
• The possibility that the merger agreement between Strive and Semler Scientific could be terminated.
• Conditions to closing the proposed transaction may not be received or satisfied on a timely basis or at all.
• The outcome of any legal proceedings that may be instituted against Strive, Semler Scientific, or the combined company.
• Anticipated benefits of the proposed transaction, including cost savings and strategic gains, may not be realized when expected or at all.
• Integration of the two companies may be more difficult, time-consuming, or costly than expected.
• The proposed transaction may be more expensive or take longer to complete than anticipated due to unexpected factors or events.
• Diversion of management's attention from ongoing business operations and opportunities due to the merger.
• Dilution caused by Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction.
• Potential adverse reactions of Strive's or Semler Scientific's customers or changes to business or employee relationships resulting from the announcement or completion of the proposed transaction.
• Changes in Strive's or Semler Scientific's share price before closing.

Future Outlook

Semler Scientific expects to complete its strategic realignment and headcount reduction by the end of calendar 2025, anticipating quarterly operating expense reductions starting January 2026. The non-executive retention program is designed to ensure continuity through the proposed merger with Strive, Inc. and the subsequent integration period. The proposed merger with Strive, Inc. is an all-stock transaction, with both companies looking towards the strategic and financial benefits of the combined entity, though subject to various risks and uncertainties. Strive, Inc. is also actively managing its capital structure through a significant preferred stock offering.

Management Comments

• Semler Scientific's board of directors approved a plan to strategically realign operations and proactively improve operating leverage through a headcount reduction and curtailment of other operating expenses.
• Semler Scientific is implementing a time-based cash retention program for its remaining non-executive employees designed to ensure continuity of clinical, regulatory, technical, and operational support functions both while the proposed merger with Strive, Inc. is pending and through any integration period post-closing.

Industry Context

The strategic realignment and cost-cutting measures by Semler Scientific suggest a move to optimize operations, potentially in preparation for or as a consequence of the pending merger with Strive, Inc. The merger itself, being an all-stock transaction, indicates a focus on strategic growth and synergy rather than immediate cash generation for the acquisition. Strive's activities, including a significant ATM offering and a dividend declaration on preferred stock, suggest a company actively managing its capital structure and potentially seeking to fund growth or provide returns to preferred shareholders, possibly to support the combined entity post-merger. The mention of Semler's Bitcoin treasury strategy indicates a diversification beyond traditional healthcare operations, aligning with a broader trend of companies exploring alternative asset holdings.

Comparison to Industry Standards

• The 37% headcount reduction by Semler Scientific is a substantial restructuring effort, often seen in companies undergoing significant strategic shifts or facing financial pressures, and is more aggressive than typical annual workforce adjustments in stable healthcare technology companies.
• The all-stock merger with Strive, Inc. is a common strategy for companies seeking to combine operations without incurring significant debt, particularly when the acquiring company (Strive) may be focused on capital-intensive activities or has a specific growth trajectory.
• Strive's use of a Controlled Equity Offering (ATM) for up to $500 million in preferred stock is a flexible capital-raising tool, often employed by growth-oriented companies to access capital opportunistically without the upfront costs and market impact of a traditional underwritten offering, which is a standard practice for companies seeking to maintain liquidity or fund strategic initiatives.
• The declaration of a dividend on preferred stock by Strive is typical for such instruments, providing a fixed income stream to investors and signaling financial stability for that class of shares.

Corporate Governance

Legal Proceedings

• The filing mentions 'the outcome of any legal proceedings that may be instituted against Strive or Semler Scientific or the combined company' as a risk factor related to the merger, but no specific current legal proceedings are detailed.

Related Party Transactions

• Strive, Inc. entered into a letter agreement with Vivek Ramaswamy on December 3, 2025, regarding the potential conversion of Strive's Class B common stock into Class A common stock.

Stakeholder Impact

• Shareholders (Semler Scientific): Potential for improved operating leverage and long-term value from cost savings and merger synergies, but also immediate dilution risk from Strive's all-stock acquisition and uncertainty surrounding merger completion and integration.
• Shareholders (Strive, Inc.): Potential for growth and diversification through the acquisition of Semler Scientific, but also risks associated with integration, increased operational complexity, and potential dilution from the preferred stock offering.
• Employees (Semler Scientific): Significant impact due to approximately 37% headcount reduction, leading to job losses. Remaining non-executive employees benefit from a retention program.
• Customers (Semler Scientific/Strive): Potential for continuity of services due to the retention program, but also risks of disruption during integration.
• Creditors: The cost-cutting measures and potential capital raise by Strive could impact the combined entity's financial health and ability to service debt, depending on the specifics.

Next Steps

• Completion of Semler Scientific's headcount reduction and operating expense curtailment by the end of calendar 2025.
• Payment of Semler Scientific's severance costs in December 2025 and January 2026.
• Realization of quarterly operating expense reductions for Semler Scientific beginning in January 2026.
• Closing of the proposed all-stock merger between Semler Scientific and Strive, Inc.
• Integration of the combined businesses of Semler Scientific and Strive, Inc.
• Strive, Inc. may offer and sell up to $500,000,000 of its Variable Rate Series A Perpetual Preferred Stock through its Controlled Equity Offering.

Key Dates

Recommendation

The filing presents a complex situation. Semler Scientific is undergoing a significant restructuring with a 37% headcount reduction, which, while aimed at improving operating leverage, signals underlying challenges and incurs immediate costs. The pending all-stock merger with Strive, Inc. introduces both potential synergies and substantial integration risks, as well as dilution for Semler shareholders. Strive's concurrent capital raising activities (ATM offering) and preferred stock dividend indicate active financial management but also potential future dilution or capital structure changes. Given the immediate costs, the uncertainty of merger completion and integration, and the significant operational changes, a 'hold' recommendation is appropriate. Investors should await further clarity on the merger's progress, the effectiveness of Semler's cost-cutting, and the combined entity's post-merger performance before making more aggressive investment decisions.

Keywords

Semler Scientific, Strive Inc, Merger, Headcount Reduction, Cost Savings, Operating Leverage, Retention Program, Bitcoin Strategy, SEC Filing, Healthcare, Preferred Stock, Dividend, Capital Raise, Corporate Restructuring